Why the study?
Do PEG-coated gold nanoparticles attenuate beta-adrenergic receptor-mediated cardiac hypertrophy in preclinical models?
Do PEG-coated gold nanoparticles attenuate beta-adrenergic receptor-mediated cardiac hypertrophy in preclinical models?
PEG-coated gold nanoparticles attenuate isoproterenol-induced cardiac hypertrophy via the ERK1/2 pathway, suggesting potential utility as both drug carriers and anti-hypertrophic agents.
May attenuate β-AR hypertrophy preclinically; leaves open clinical translation and requires prospective validation.
Gold nanoparticles (AuNPs) are widely used as a drug delivery vehicle, which can accumulate in the heart through blood circulation. Therefore, it is very important to understand the effect of AuNPs on the heart, especially under pathological conditions. In this study, we found that PEG-coated AuNPs attenuate β-adrenergic receptor (β-AR)-mediated acute cardiac hypertrophy and inflammation. However, both isoproterenol, a non-selective β-AR agonist, and AuNPs did not induce cardiac function change or cardiac fibrosis. AuNPs exerted an anti-cardiac hypertrophy effect by decreasing β 1 -AR expression and its downstream ERK1/2 hypertrophic pathway. Our results indicated that AuNPs might be safe and have the potential to be used as multi-functional materials (drug carrier systems and anti-cardiac hypertrophy agents).
No takes yet. Share an insight, caveat, or question.
Qiao et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: